Table 2.

Adverse events in patients treated on the nonsurgical arm (N = 20)*

	All Adverse Events		Possibly/Probably Related
Adverse Events, N (%)	All Grades	Grades 3–4	All Grades	Grades 3–4
Nervous system disorders
Headache	10 (50%)	0 (0%)	0 (0%)	0 (0%)
Nervous system disorders, other	6 (30%)	0 (0%)	0 (0%)	0 (0%)
Dizziness	4 (20%)	0 (0%)	1 (5%)	0 (0%)
Memory impairment	4 (20%)	0 (0%)	0 (0%)	0 (0%)
Seizure	4 (20%)	0 (0%)	0 (0%)	0 (0%)
Paresthesia	3 (15%)	0 (0%)	0 (0%)	0 (0%)
Metabolism and nutrition disorders
Hypophosphatemia	9 (45%)	0 (0%)	7 (35%)	0 (0%)
Hyperglycemia	8 (40%)	0 (0%)	0 (0%)	0 (0%)
Anorexia	4 (20%)	0 (0%)	3 (15%)	0 (0%)
General disorders and administration site conditions
Gait disturbance	8 (40%)	1 (5%)	4 (20%)	0 (0%)
Fatigue	7 (35%)	0 (0%)	0 (0%)	0 (0%)
Injury, poisoning, and procedural complications
Fall	8 (40%)	1 (5%)	0 (0%)	0 (0%)
Gastrointestinal disorders
Nausea	7 (35%)	0 (0%)	5 (25%)	0 (0%)
Vomiting	7 (35%)	0 (0%)	5 (25%)	0 (0%)
Gastrointestinal disorders, other	6 (30%)	1 (5%)	0 (0%)	0 (0%)
Diarrhea	5 (25%)	0 (0%)	5 (25%)	0 (0%)
Dysphagia	3 (15%)	0 (0%)	0 (0%)	0 (0%)
Investigations
Platelet count decreased	6 (30%)	0 (0%)	1 (5%)	0 (0%)
Psychiatric disorders
Confusion	5 (25%)	0 (0%)	1 (5%)	0 (0%)
Insomnia	4 (20%)	0 (0%)	0 (0%)	0 (0%)
Musculoskeletal and connective tissue disorders
Muscle weakness right-sided	4 (20%)	0 (0%)	0 (0%)	0 (0%)
Muscle weakness left-sided	3 (15%)	2 (10%)	0 (0%)	0 (0%)
Muscle weakness lower limb	3 (15%)	0 (0%)	0 (0%)	0 (0%)
Infections and infestations
Urinary tract infection	3 (15%)	1 (5%)	0 (0%)	0 (0%)
Vascular disorders
Hypertension	3 (15%)	2 (10%)	0 (0%)	0 (0%)

*Adverse events by CTCAE reported in >10% of patients.